PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
9.62%
Cash & equivalents yoy growth below half of GNPX's 21.96%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
9.62%
Below half of GNPX's 21.96%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of GNPX's 22.52%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.18%
Below half GNPX's -48.81%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.96%
Higher Long-Term Investments Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.38%
Below half of GNPX's 6.30%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Below half of GNPX's 17.75%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-5.53%
Less than half of GNPX's 53.99%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
6569.50%
Higher Deferred Revenue (Current) Growth compared to GNPX's zero value, indicating better performance.
100.00%
Less than half of GNPX's -10.82%. David Dodd sees fewer expansions in other current obligations.
-5.06%
Less than half of GNPX's 17.01%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2126.46%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.39%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-1.27%
Less than half of GNPX's 17.01%. David Dodd sees far fewer liability expansions relative to competitor.
3.57%
Less than half of GNPX's 29.41%. David Dodd sees fewer share issuances vs. competitor.
-2.57%
0.5-0.75x GNPX's -4.46%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.56%
1.25-1.5x GNPX's 18.07%. Bruce Berkowitz notes an above-average equity expansion.
8.48%
Below half GNPX's 17.75%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.96%
Higher Total Investments Growth compared to GNPX's zero value, indicating better performance.
-6.20%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
-10.07%
Less than half of GNPX's -21.96%. David Dodd sees better deleveraging or stronger cash buildup than competitor.